Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, Entero Therapeutics Inc increased its cash reserves by 169.66%, or 2.35m. Cash Flow from Financing totalled 15.23m or -- of revenues. In addition the company used 12.38m for operations while cash used for investing totalled 500.00k.
Cash flow per share | -1.62 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 38.45 |
---|---|
Tangible book value per share | -2.74 |
More ▼
Balance sheet in USDView more
Current ratio | 1.21 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.0871 |
---|---|
Total debt/total capital | 0.0802 |
More ▼